Antimicrobial Agents and Chemotherapy, January 2008, p. 329-332, Vol. 52, No. 1
0066-4804/08/$08.00+0 doi:10.1128/AAC.01004-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro
Robert A. Smith,1*
Geoffrey S. Gottlieb,2
Donovan J. Anderson,1
Crystal L. Pyrak,1 and
Bradley D. Preston1
Departments of Pathology,1
Medicine, University of Washington, Seattle, Washington2
Received 31 July 2007/
Returned for modification 14 September 2007/
Accepted 23 October 2007
Using an indicator cell assay that directly quantifies viral replication, we show that human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2, respectively) exhibit similar sensitivities to 3'-azido-3'-deoxythymidine (zidovudine) as well as other nucleoside analog inhibitors of reverse transcriptase. These data support the use of nucleoside analogs for antiviral therapy of HIV-2 infection.
* Corresponding author. Mailing address: University of Washington, Department of Pathology, K-046 HSB, Box 357705, 1959 NE Pacific St., Seattle, WA 98195. Phone: (206) 221-5650. Fax: (206) 543-3967. E-mail: smithra{at}u.washington.edu
Published ahead of print on 29 October 2007.
Antimicrobial Agents and Chemotherapy, January 2008, p. 329-332, Vol. 52, No. 1
0066-4804/08/$08.00+0 doi:10.1128/AAC.01004-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Copyright © 2008 by the American Society for Microbiology. All rights reserved.